Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 44Lymphoma, Mantle-Cell 22Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma 9Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Recurrence 6Neoplasms 6Lymphoma, B-Cell 5Leukemia, B-Cell 5Bronchiolitis Obliterans Syndrome 5Multiple Myeloma 3Leukemia, Lymphoid 3Hematologic Diseases 3Graft vs Host Disease 3Burkitt Lymphoma 3Melanoma 2Leukemia, Prolymphocytic 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Glioblastoma 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1

Interventions

Magnetic Resonance Spectroscopy 9Cyclophosphamide 7X-Rays 6Temozolomide 6Specimen Handling 6Phantoms, Imaging 6Biopsy 6Nuclear Medicine Department, Hospital 5Etoposide 5Nivolumab 4Bevacizumab 4Radiation 3Irinotecan 3Automobiles 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2lutetium Lu 177 dotatate 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2abemaciclib 2Watchful Waiting 2Radiotherapy 2ONC206 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × ibrutinib × 1 year × Clear all
NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Augusta University

Phase 1 Recruiting
37 enrolled
CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡